Abstract
IntroductionImmune checkpoint inhibitors (ICIs) have become a frontier in the field of clinical technology for advanced non-small cell lung cancer (NSCLC). Currently, the predictive biomarker of ICIs mainly including the expression of PD-L1, TMB, TIICs, MMR and MSI-H. However, there are no official biomarkers to guide the treatment of ICIs and to determine the prognosis. Therefore, it is essential to explore a systematic nomogram to predict the prognosis of ICIs treatment in NSCLCMethodsIn this work, we obtained gene expression and clinical data of NSCLC patients from the TCGA database. Immune-related genes (IRGs) were downloaded from the ImmPort database. The detailed clinical annotation and response data of 240 advanced NSCLC patients who received ICIs treatment were obtained from the cBioPortal for Cancer Genomics. Kaplan–Meier survival analysis was used to perform survival analyses, and selected clinical variables to develop a novel nomogram. The prognostic significance of FGFR4 was validated by another cohort in cBioPortal for Cancer Genomics.Results3% of the NSCLC patients harbored FGFR4 mutations. The mutation of FGFR4 were confirmed to be associated with PD-L1, and TMB. Patients harbored FGFR4 mutations were found to have a better prolonged progression-free survival (PFS) to ICIs treatment (FGFR4: P = 0.0209). Here, we built and verified a novel nomogram to predict the prognosis of ICIs treatment for NSCLC patients.ConclusionOur results showed that FGFR4 could serve as novel biomarkers to predict the prognosis of ICIs treatment of advanced NSCLC. Our systematic prognostic nomogram showed a great potential to predict the prognosis of ICIs for advanced NSCLC patients.
Highlights
Immune checkpoint inhibitors (ICIs) have become a frontier in the field of clinical technology for advanced non-small cell lung cancer (NSCLC)
Our results showed that Fibroblast growth factor receptor 4 (FGFR4) could serve as novel biomarkers to predict the prognosis of ICIs treatment of advanced NSCLC
FGFR4 was associated with the prognosis of NSCLC patients with ICIs treatment
Summary
Immune checkpoint inhibitors (ICIs) have become a frontier in the field of clinical technology for advanced non-small cell lung cancer (NSCLC). It is essential to explore a systematic nomogram to predict the prognosis of ICIs treatment in NSCLC. Lung cancer was mainly divided into two types: non-small-cell lung cancer (NSCLC) and. Wang et al J Transl Med (2021) 19:22 small cell lung cancer (SCLC). NSCLC accounts for more than 85% of lung cancer. Traditional treatment of NSCLC mainly including surgery, radiotherapy, chemotherapy and targeted therapy. The mutations of tumor-driving genes such as EGFR, BRAF, ERBB2 and rearrangement of ALK or ROS1 only exist in less than half of NSCLC patients, which suitable for receiving targeted therapy [3]. For advanced NSCLC patients who cannot be treated with surgery or targeted drugs, platinum-based chemotherapy has been used as a standard treatment [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
